Background. The number of persons in rehabilitation after multi-organ, multifocal injuries increases every year. The purpose of this article is to draw attention to the orthopedic problems associated with the treatment of these patients. Material and methods. The article present clinical material consisting of all patients rehabilitated for multi-organ injuries in the First Department of Rehabilitation at the Metropolitan Rehabilitation Center in Konstancin, Poland, from 1989-2000. The clinical problems posed by rehabilitation were addressed by a team of specialists, including physicians (mostly orthopedists and rehabilitation specialists), physiotherapists, psychologists, social workers, and a large nursing staff. Results. The article attempts to sum up the results of our efforts, to evaluate our effectiveness, and to challenge some still-existing therapeutic stereotypes in the treatment of these patients. Conclusions. The most effective rehabilitation is early, multi-level, and team-based. An essential role is also played by psychotherapy, social care, and efforts to help the individual rebuild a sense of his/her own value, accept athe handicap, and find a new place in society. Bedside nursing is decisive for the patient's physical and mental comfort, and for the prevention of complications. The restoration of locomotor and self-service skills is the easiest task, while the hardest is recovering full mobility in the distal joints.

Download full-text PDF

Source

Publication Analysis

Top Keywords

treatment patients
8
rehabilitation
6
comprehensive rehabilitation
4
patients
4
rehabilitation patients
4
patients multi-organ
4
multi-organ multi-focal
4
multi-focal injuries
4
injuries background
4
background number
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Suven Life Sciences, Hyderabad, Telangana, India.

Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Biogen, Cambridge, MA, USA.

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of tau aggregates. Research in animal models has generated hypotheses on the underlying mechanisms of the interaction between Aβ and tau pathology. In support of this interaction, results from clinical trials have shown that treatment with anti-Aβ monoclonal antibodies (mAbs) affects tau pathology.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Fundacion Neuropolis, Zaragoza, Zaragoza, Spain.

Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China.

Background: The DL-3-n-butylphthalide (NBP), a multi-target neuroprotective drug, improving cognitive impairment in patient with vascular cognitive impairment has been confirmed. The efficacy of NBP in patients with cognitive impairment due to Alzheimer's disease (AD) remains unknown. This study aimed to evaluate the efficacy and safety of NBP in patients with mild cognitive impairment (MCI) due to AD though a clinical randomized controlled trail.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Columbia University, New York, NY, USA.

Background: Focused ultrasound (FUS)-induced blood-brain barrier opening (BBBO) is a technique for safely, non-invasively, and transiently opening the blood brain barrier in a targeted area of the brain. Pre-clinical and clinical studies have shown that FUS is capable of decreasing amyloid plaque load and stimulating neurogenesis in Alzheimer's Disease (AD) models, in addition to being safe for use in human patients. However, the effect of FUS-BBBO on neurons has not yet been characterized, despite its crucial role in cognition and regulating brain function.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!